Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 172 clinical trials
Phase I-II Trial of Sorafenib in Combination With Ifosfamide in Soft Tissue Sarcoma

models of sarcoma (7,8). For these reasons, inhibition of VEGFR seems to be a reasonable approach to explore in the treatment of STS. Sorafenib (BAY 43-9006) is an orally available, small

neutrophil count
anthracyclines
dacarbazine
monoclonal antibodies
doxorubicin
  • 13 views
  • 07 Nov, 2020
  • 1 location
Salvage Therapy With Sunitinib Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung Cancer

study treated with VEGF-directed monoclonal antibody (bevacizumab) and VEGFR and platelet-derived growth factor receptor (PDGFR) small molecule inhibitors (sunitinib) showed that some non

serum bilirubin level
neutrophil count
solid tumour
bevacizumab
carcinoma
  • 2 views
  • 08 Nov, 2020
  • 1 location
Radium-223 in Biochemically Recurrent Prostate Cancer

biochemically recurrent prostate cancer. Radium-223 is a small molecule. It uses radiation to kill cancer cells and improves survival in advanced prostate cancer. Researchers want to see if it can treat

  • 0 views
  • 22 Mar, 2021
  • 1 location
Safety and Pharmacokinetics of JAK/ROCK Inhibitor in Healthy Volunteers

), called CPL409116.Janus kinase (JAK) inhibitors are a new class of small molecule drugs that modulate inflammatory pathways by blocking one or more JAK receptors. In recent years, JAK inhibitors have

  • 0 views
  • 27 Jan, 2021
  • 1 location
Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer

This research is being done to see if an investigational radioactive imaging agent (radiotracer) called 18F-DCFPyL can help us find prostate cancer at its original site in the prostate gland and in distant sites (bone, lymph nodes) in men diagnosed with prostate cancer before surgery.

  • 0 views
  • 10 Mar, 2021
  • 1 location
Study To antagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19

This is a single-center, randomized double blind placebo controlled trial to evaluate the efficacy and safety of novel PAI-1 inhibitor (TM5614) for high-risk patients hospitalized with severe COVID-19 at Northwestern Memorial Hospital. The patients will be randomized in a 1:1 ratio to receive standard of care plus TM5614 or standard …

  • 0 views
  • 03 Feb, 2021
  • 1 location
A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous Chemotherapy

This is a single center, open-labeled, single arm phase II study aimed to investigate the efficacy and safety of fruquintinib combined with capecitabine as first-line treatment for advanced metastatic colorectal cancer patients unsuitable for intravenous chemotherapy.

  • 0 views
  • 05 May, 2021
  • 1 location
A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions

A Phase 1 dose escalation study to evaluate APR003 in patients with advanced colorectal cancer (CRC) with malignant liver lesions

  • 0 views
  • 10 May, 2021
  • 3 locations
APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma

This study is a two stage study consisting of a dose escalation phase Ib and a phase II study which include subjects with previously-treated, advanced pancreatic adenocarcinoma. Dose Limiting Toxicities (DLTs) and maximum tolerated dose (MTD) of APG1387 in combination with nab-paclitaxel and gemcitabine will be evaluated in the dose …

  • 0 views
  • 08 May, 2021
  • 1 location
Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor Copanlisib Given in Combination With the Immunotherapeutic Agents Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma

Patients with relapsed or refractory follicular or marginal zone lymphoma who have received at least one prior line of therapy will receive Copanlisib IV: day 1, 8, 15 every 28 days Nivolumab IV: Cycle 1 days 1 and 15; then day 1 only Rituximab IV: Cycle 1 days 1, 8, …

  • 0 views
  • 27 Jan, 2021
  • 2 locations